Neuren Media and Analyst Coverage, page-719

Hi Tony

I am well aware it is an opinion game but I was asked to provide my numbers. Hence the importance of the % chance of success which as I have stated is the single most important variable. If all indications become commercial the share price will be well north of $264 the model attempts to take this into account.

As for % chance of PMS gaining FDA approval from here I beg to differ. Yes you can quote 53% of positive phase 2 results progressing to phase 3 success, but show me a compound with the animal models NNZ- 2591 has, the strength and consistency of the PMS phase 2 results, the statistical significance/power generated by 18 subjects in an area of medicine where there is no approved treatment and any improvement is seen as significant PLUS a similar first in class molecule performing admirably in a similar condition - and I will show you a compound with a COS much closer to 100% than 50%.

IMO but this is actually my wheelhouse in the real world.